Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  O'Leary, Ben ^a,b   Hrebien, Sarah ^a   Morden, James P ^a   Beaney, Matthew ^a   Fribbens, Charlotte ^a,b   Huang, Xin ^c   Liu, Yuan ^c   Bartlett, Cynthia Huang ^c   Koehler, Maria ^c   Cristofanilli, Massimo ^d   Garcia Murillas, Isaac ^a   Bliss, Judith M ^a   Turner, Nicholas C ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c PFIZER INC   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING TUMOR DNA; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

BIOMARKER; CANCER; CHEMORECEPTION; DNA; ENZYME; ESTROGENIC COMPOUND; HETEROGENEITY; INHIBITION; MUTATION; PLASMA; SURVIVAL; TUMOR;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CLONAL EVOLUTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; HAZARD RATIO; HORMONAL THERAPY; HUMAN; LOG RANK TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PIK3CA GENE; PREDICTION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CIRCULATING TUMOR DNA; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CYCLIN-DEPENDENT KINASE 6; DISEASE-FREE SURVIVAL; ESTRADIOL; FEMALE; HUMANS; PIPERAZINES; PYRIDINES; RECEPTORS, ESTROGEN;

EID: 85042846495     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-03215-x     Document Type: Article

References (40)

1. Dawson, S.-J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. New Engl. J. Med. 368, 1199-1209 (2013)
2. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013)
3. Forshew, T. et al. Noninvasive Identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 4, 136ra168 (2012)
4. Mok, T. et al. Detection and dynamic changes of egfr mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin. Cancer Res. 21, 3196-3203 (2015)
5. Garcia-Murillas, I. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015)
6. Douillard, J. Y. et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br. J. Cancer 110, 55-62 (2014)
7. Murtaza, M. et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun. 6, 8760 (2015)
8. Tie, J. et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 26, 1715-1722 (2015)
9. Garlan, F. et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin. Cancer Res. 23, 5416-5425 (2017)
10. Marchetti, A. et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J. Thorac. Oncol. 10, 1437-1443 (2015)
11. Schreuer, M. et al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. J. Transl. Med. 14, 95 (2016)
12. Kato, K. et al. Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients. Sci. Rep. 6, 29093 (2016)
13. Imamura, F. et al. Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment. Oncotarget 7, 71782-71789 (2016)
14. Diaz, L. A. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579-586 (2014)
15. Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548-554 (2014)
16. Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature 545, 446-451 (2017)
17. Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445 (2013)
18. Fanning, S. W. et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. eLife 5, e12792 (2016)
19. Jeselsohn, R. et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 20, 1757-1767 (2014)
20. Schiavon, G. et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. 7, 313ra182 (2015)
21. Fribbens, C. et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 34, 2961-2968 (2016)
22. Chandarlapaty, S. et al. Prevalence of ESR1 mutations in cell-free dna and outcomes in metastatic breast cancer: a secondary analysis of the bolero-2 clinical trial. JAMA Oncol. 2, 1310-1315 (2016)
23. Spoerke, J. M. et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat. Commun. 7, 11579 (2016)
24. Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. New Engl. J. Med. 375, 1925-1936 (2016)
25. Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17 425-439 (2016)
26. Hortobagyi, G. N. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New Engl. J. Med. 375, 1738-1748 (2016)
27. O'Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4/6 inhibitors. Nat. Rev. Clin. Oncol. 13, 417-430 (2016)
28. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013)
29. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401 (2012)
30. Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479 (2016)
31. Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751-759 (2015)
32. Yates, L. R. et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 32, 169-184.e167 (2017)
33. Higgins, M. J. et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 18, 3462-3469 (2012)
34. Baselga, J. et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 904-916 (2017)
35. Ciriello, G. et al. Comprehensive molecular portraits of invasive lobular breast. Cancer Cell. 163, 506-519 (2015)
36. Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M. & Schiff, R. ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat. Rev. Clin. Oncol. 12, 573-583 (2015)
37. Finn, R. S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25-35 (2015)
38. Finn, R. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, R77 (2009)
39. Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. USA 108, 9530-9535 (2011)
40. Turner, N. C., et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209-219 (2015).